336 related articles for article (PubMed ID: 29041951)
1. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
[TBL] [Abstract][Full Text] [Related]
2. Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients.
Saito S; Suzuki K; Yoshimoto K; Kondo Y; Kikuchi J; Hanaoka H; Kaneko Y; Takeuchi T
Clin Exp Rheumatol; 2023 Jul; 41(7):1451-1455. PubMed ID: 36533996
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.
Li S; Wu Z; Li L; Liu X
Med Sci Monit; 2016 Jun; 22():2113-8. PubMed ID: 27322646
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
Kikuchi J; Hashizume M; Kaneko Y; Yoshimoto K; Nishina N; Takeuchi T
Arthritis Res Ther; 2015 Jan; 17(1):10. PubMed ID: 25604867
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
6. IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis.
Anderson AE; Pratt AG; Sedhom MA; Doran JP; Routledge C; Hargreaves B; Brown PM; Lê Cao KA; Isaacs JD; Thomas R
Ann Rheum Dis; 2016 Feb; 75(2):466-73. PubMed ID: 25649145
[TBL] [Abstract][Full Text] [Related]
7. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
8. Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion.
Guggino G; Giardina AR; Raimondo S; Giardina G; Sireci G; Dieli F; Peralta M; Alessandro R; Triolo G; Ciccia F
Clin Exp Rheumatol; 2014; 32(1):77-81. PubMed ID: 24429356
[TBL] [Abstract][Full Text] [Related]
9. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
[TBL] [Abstract][Full Text] [Related]
10. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
11. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo.
Wright HL; Cross AL; Edwards SW; Moots RJ
Rheumatology (Oxford); 2014 Jul; 53(7):1321-31. PubMed ID: 24609058
[TBL] [Abstract][Full Text] [Related]
12. Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis.
Kuuliala K; Kuuliala A; Koivuniemi R; Oksanen S; Hämäläinen M; Moilanen E; Kautiainen H; Leirisalo-Repo M; Repo H
PLoS One; 2015; 10(9):e0137385. PubMed ID: 26353115
[TBL] [Abstract][Full Text] [Related]
13. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation.
Saito Y; Kagami S; Sanayama Y; Ikeda K; Suto A; Kashiwakuma D; Furuta S; Iwamoto I; Nonaka K; Ohara O; Nakajima H
Arthritis Rheumatol; 2014 May; 66(5):1185-94. PubMed ID: 24782182
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage.
Richez C; Barnetche T; Khoryati L; Duffau P; Kostine M; Contin-Bordes C; Blanco P; Schaeverbeke T
J Rheumatol; 2012 Jun; 39(6):1192-7. PubMed ID: 22467922
[TBL] [Abstract][Full Text] [Related]
15. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.
Lee SJ; Park W; Park SH; Shim SC; Baek HJ; Yoo DH; Kim HA; Lee SK; Leee YJ; Park YE; Cha HS; Park JK; Lee EY; Lee EB; Song YW
J Immunol Res; 2015; 2015():487230. PubMed ID: 25922848
[TBL] [Abstract][Full Text] [Related]
16. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis.
Aizu M; Mizushima I; Nakazaki S; Nakashima A; Kato T; Murayama T; Kato S; Katsuki Y; Ogane K; Fujii H; Yamada K; Nomura H; Yachie A; Yamagishi M; Kawano M
Mod Rheumatol; 2018 Jul; 28(4):592-598. PubMed ID: 28880691
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Smolen JS; Avila JC; Aletaha D
Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
[TBL] [Abstract][Full Text] [Related]
20. Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis.
Saito S; Kaneko Y; Izumi K; Takeuchi T
J Rheumatol; 2017 May; 44(5):553-557. PubMed ID: 28298563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
